ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,054.85
0.73%
Dow Jones
38,143.97
0.63%
US Dollar vs MXN
16.95125
0.05%
Brent Oil
83.665
0.15%
Bitcoin
58,691.31
0.78%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Immunovant Inc (IMVT)

  7. Immunovant Inc (IMVT) Noticias

IMVT Immunovant Inc

28.52
0.00 (0.00%)
Pre Mercado
Última actualización: 05:46:57
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Immunovant Inc IMVT NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 28.52 05:46:57
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
28.52
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
12/3/202406:30GLOBEImmunovant Awarded U.S. Patent for IMVT-1402
23/2/202415:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202415:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202415:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202407:47EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202406:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/2/202406:02EDGAR2Form 8-K - Current report
29/1/202415:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202415:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/1/202406:29EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/1/202415:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202415:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202415:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202407:08EDGAR2Form 8-K - Current report
03/1/202407:00GLOBEImmunovant to Present at the 42nd Annual J.P. Morgan..
20/12/202316:40DJNImmunovant Gets Positive Data From Graves' Disease Treatment..
20/12/202315:37EDGAR2Form 8-K - Current report
20/12/202315:30GLOBEImmunovant Reports Positive Initial Phase 2 Results for..
28/11/202306:43EDGAR2Form 8-K - Current report
28/11/202306:00GLOBEImmunovant Announces Positive IMVT-1402 Initial 600 mg MAD..
24/11/202313:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/11/202313:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/11/202313:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/11/202313:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202307:00GLOBEImmunovant to Present at Upcoming Investor Conferences
09/11/202307:49EDGAR2Form S-3ASR - Automatic shelf registration statement of..
09/11/202306:13EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202306:06EDGAR2Form 8-K - Current report
09/11/202306:00GLOBEImmunovant Reports Financial Results and Provides Corporate..
20/10/202315:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/10/202315:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202316:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202316:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/10/202315:52GLOBEImmunovant Announces Closing of Upsized Common Stock..
29/9/202315:48EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/9/202316:23EDGAR2Form 8-K - Current report
28/9/202305:09EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
27/9/202322:41GLOBEImmunovant Announces Pricing of $450 Million Common Stock..
26/9/202316:28EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
26/9/202316:00GLOBEImmunovant Announces Proposed Offering of $300 Million of..
26/9/202306:45EDGAR2Form 8-K - Current report
26/9/202305:00GLOBEImmunovant Announces Positive Initial IMVT-1402 Phase 1 SAD..
25/9/202322:01GLOBEImmunovant to Host Conference Call and Webcast to Report..
01/9/202315:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/8/202316:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/8/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/8/202315:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/8/202315:48EDGAR2Form 8-K - Current report
16/8/202315:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202306:19EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Su Consulta Reciente

NASDAQ
IMVT
Immunovant
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados